<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03688555</url>
  </required_header>
  <id_info>
    <org_study_id>ID-084A201</org_study_id>
    <secondary_id>2018-000851-42</secondary_id>
    <nct_id>NCT03688555</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 12-week Treatment Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the&#xD;
      safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 12 in NPS as measured by nasal endoscopy assessed centrally</measure>
    <time_frame>From baseline to up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in sinus opacifications as assessed by CT scan using the Zinreich-modified Lund Mackay Score assessed centrally</measure>
    <time_frame>From baseline to up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in 3D volumetric computerized values</measure>
    <time_frame>From baseline to up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 2 in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>From baseline to up to 2 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 4 in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>From baseline to up to 4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 8 in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>From baseline to up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>From baseline to up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to EOS in University of Pennsylvania Smell Identification Test (UPSIT)</measure>
    <time_frame>From baseline to up to 20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 2 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain</measure>
    <time_frame>From baseline to up to 2 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 4 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain</measure>
    <time_frame>From baseline to up to 4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 8 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain</measure>
    <time_frame>From baseline to up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain</measure>
    <time_frame>From baseline to up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to EOS in the sum of Visual Analog Scale (VAS) symptoms score for nasal obstruction, nasal discharge, mucus in the throat, loss of smell, and facial pain</measure>
    <time_frame>From baseline to up to 20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 2 in Physician Global Assessment (PGA) score</measure>
    <time_frame>from baseline to up to 2 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 4 in Physician Global Assessment (PGA) score</measure>
    <time_frame>from baseline to up to 4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 8 in Physician Global Assessment (PGA) score</measure>
    <time_frame>from baseline to up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in Physician Global Assessment (PGA) score</measure>
    <time_frame>from baseline to up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to EOS in Physician Global Assessment (PGA) score</measure>
    <time_frame>From baseline to up to 20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 2 in SNOT-22.</measure>
    <time_frame>from baseline to up to 2 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 4 in SNOT-22.</measure>
    <time_frame>from baseline to up to 4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 8 in SNOT-22.</measure>
    <time_frame>from baseline to up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in SNOT-22.</measure>
    <time_frame>from baseline to up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to EOS in SNOT-22.</measure>
    <time_frame>From baseline to up to 20 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change in disease severity at Week 2</measure>
    <time_frame>from baseline to up to 2 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change in disease severity at Week 4</measure>
    <time_frame>from baseline to up to 4 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change in disease severity at Week 8</measure>
    <time_frame>from baseline to up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change in disease severity at Week 12</measure>
    <time_frame>from baseline to up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of change in disease severity at EOS</measure>
    <time_frame>From baseline to up to 20 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Bilateral Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>ACT-774312</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ACT-774312 400 mg b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-774312</intervention_name>
    <description>ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312</description>
    <arm_group_label>ACT-774312</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in the local language prior to any study mandated procedure.&#xD;
&#xD;
          -  A minimum bilateral nasal polyp score (NPS) of 5 out of a maximum of 8 for both&#xD;
             nostrils (with at least a score of 2 for each nostril) despite completion of a prior&#xD;
             intranasal corticosteroids (INCS) treatment for at least 8 weeks before screening,&#xD;
             with at least the 6 last weeks on INCS spray.&#xD;
&#xD;
          -  Presence of at least 2 of the following symptoms at screening:&#xD;
&#xD;
               -  nasal blockade/obstruction&#xD;
&#xD;
               -  nasal discharge (anterior/posterior nasal drip)&#xD;
&#xD;
               -  reduction or loss of smell.&#xD;
&#xD;
          -  Male and female subjects aged between 18 and 70 years (inclusive) at screening.&#xD;
&#xD;
          -  Systolic blood pressure 90 to 160 mmHg, diastolic blood pressure 50 to 100 mmHg, pulse&#xD;
             rate 45 to 100 bpm (inclusive), measured on the dominant arm, after 5 minutes in the&#xD;
             supine position at screening.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at screening&#xD;
             and a negative urine pregnancy test predose on Day 1. Women of childbearing potential&#xD;
             must consistently and correctly use (from at least first dosing, during the entire&#xD;
             study, and for at least 30 days after last study treatment intake) 1 highly effective&#xD;
             method of contraception with a failure rate of &lt; 1% per year, be sexually abstinent,&#xD;
             or have a vasectomized partner. Hormonal contraceptive must have been initiated at&#xD;
             least 1 month before first study treatment administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CYP2C9 poor metabolizer subject.&#xD;
&#xD;
          -  Subject with severe renal function impairment (≤ 29 mL/min/1.73 m2) which is defined&#xD;
             by eGFR estimated at screening using the Modification of Diet in Renal Disease (MDRD)&#xD;
             formula.&#xD;
&#xD;
          -  Subject with Sino-Nasal Outcome Test (SNOT-22) &lt;20.&#xD;
&#xD;
          -  Subject who has required oral corticosteroids (OCS) within the 2 months before&#xD;
             screening or is scheduled to receive OCS during the study period for another&#xD;
             condition.&#xD;
&#xD;
          -  Subject who has required INCS drops within the 6 weeks before screening.&#xD;
&#xD;
          -  Subject who was injected with long-lasting activity corticosteroids within the 3&#xD;
             months before screening or is scheduled to receive these during the study period for&#xD;
             another condition.&#xD;
&#xD;
          -  Subject who has undergone any nasal surgery within 6 months before screening.&#xD;
&#xD;
          -  Subjects with conditions/concomitant diseases making them nonevaluable for the primary&#xD;
             efficacy endpoint such as:&#xD;
&#xD;
               -  Antrochoanal polyps&#xD;
&#xD;
               -  Nasal septal deviation that occludes at least one nostril&#xD;
&#xD;
               -  Acute sinusitis, nasal infection or upper respiratory infection at screening or&#xD;
                  in the 2 weeks before screening&#xD;
&#xD;
               -  Ongoing rhinitis medicamentosa&#xD;
&#xD;
               -  Churg-Strauss syndrome, Young's syndrome, Kartagener's syndrome or dyskinetic&#xD;
                  ciliary syndromes, Cystic fibrosis&#xD;
&#xD;
               -  Signs or a CT scan suggestive of Allergic fungal rhinosinusitis.&#xD;
&#xD;
          -  Subjects with co-morbid asthma are excluded if:&#xD;
&#xD;
               -  Forced expiratory volume in one second (FEV1) ≤ 60% of predicted normal OR&#xD;
&#xD;
               -  An exacerbation requiring systemic (oral and/or parenteral) steroid treatment or&#xD;
                  hospitalization (&gt;24 h) for treatment of asthma has occurred within 3 months&#xD;
                  prior screening OR&#xD;
&#xD;
               -  They are on a dose higher than 1000 μg fluticasone or the equivalent of inhaled&#xD;
                  corticosteroids (ICS).&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  Subject with active autoimmune disease (e.g., Hashimoto's thyroiditis, Graves'&#xD;
             disease, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus&#xD;
             erythematosus, multiple sclerosis, psoriasis vulgaris, rheumatoid arthritis).&#xD;
&#xD;
          -  Subject considered as vulnerable (e.g., sponsor or site employee, investigator&#xD;
             subordinate, subject incapable of giving consent, subject committed to an institution&#xD;
             by way of official or judicial order).&#xD;
&#xD;
          -  Subject with liver injury related criteria:&#xD;
&#xD;
               -  Underlying hepatobiliary disease OR&#xD;
&#xD;
               -  ALT&gt;3 ULN OR&#xD;
&#xD;
               -  or Bilirubin&gt;2 ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 12, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

